Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AAV gene therapy
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Weizmann Institute of Science
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 02, 2020
Details:
The agreement involves collaboration, with the aim of developing a novel AAV gene therapy approach for neuronopathic Gaucher disease, Parkinson disease, and other diseases associated with mutations of the GBA1 gene.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Servier
Deal Size: $363.3 million Upfront Cash: $3.3 million
Deal Type: Partnership February 17, 2020
Details:
The partnership drew on the complementary expertise of Servier and Oncodesign in the fields of neurodegenerative diseases and macrocyclic kinase inhibitors.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
